2014
DOI: 10.1016/j.lungcan.2014.06.013
|View full text |Cite
|
Sign up to set email alerts
|

Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
1
1

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 33 publications
(33 citation statements)
references
References 18 publications
0
29
1
1
Order By: Relevance
“…8 The data used in this study are derived from a de-identified NCDB file, The American College of Surgeons and the Commission on Cancer have not verified and are neither responsible for the analytic or statistical methodology employed nor the conclusions drawn from these data by the investigator. The NCDB records information regarding approximately 70% of newly diagnosed cancers in the United States, including treatment details such as sequencing of therapies, dose, technique, and target.…”
Section: National Cancer Databasementioning
confidence: 99%
“…8 The data used in this study are derived from a de-identified NCDB file, The American College of Surgeons and the Commission on Cancer have not verified and are neither responsible for the analytic or statistical methodology employed nor the conclusions drawn from these data by the investigator. The NCDB records information regarding approximately 70% of newly diagnosed cancers in the United States, including treatment details such as sequencing of therapies, dose, technique, and target.…”
Section: National Cancer Databasementioning
confidence: 99%
“…It contains deidentified information from approximately 70% of newly diagnosed cancers in the United States. The NCDB contains information that is unavailable in the Surveillance, Epidemiology, and End Results database, including treatment details pertaining to radiation therapy dose, technique, and target (16). The data used in this study are derived from a deidentified NCDB file.…”
Section: Study Design and Data Sourcementioning
confidence: 99%
“…However, there are no randomized trials comparing ablative therapies to surgery (67), and recent studies of SBRT versus sublobar resection were terminated early due to poor accrual (68). Because of the risks and challenges of biopsy in marginal surgical candidates, many patients with nodules undergo ablative therapy without a diagnosis of lung cancer (69). It will be important to compare the efficacy and effectiveness of emerging therapies to surgery to guide decision-making about the risks and benefits of different evaluation strategies and treating patients with pulmonary nodules that may not be cancerous.…”
Section: Emerging Treatmentsmentioning
confidence: 99%